89bio, Inc. Presents New Data From Phase 2b ENLIVEN Trial of Pegozafermin for Advanced MASH at AASLD 2024
89bio, Inc. Presents New Data From Phase 2b ENLIVEN Trial of Pegozafermin for Advanced MASH at AASLD 2024
89bio presented new Phase 2b trial data on pegozafermin for treating advanced MASH, highlighting potential benefits in fibrosis reversal.
89bio展示了有关pegozafermin治疗高级MASH的新20亿期试验数据,强调了其在纤维化逆转中的潜在益处。
Quiver AI Summary
Quiver AI 概要
89bio, Inc. announced new analyses from its Phase 2b ENLIVEN trial of pegozafermin, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. The findings, presented at The Liver Meeting in San Diego, suggest pegozafermin's effectiveness in reversing fibrosis and preventing progression to cirrhosis. Chief Medical Officer Hank Mansbach expressed excitement over the results, while Dr. Naim Alkhouri emphasized the potential of non-invasive tests to identify high-risk patients. The trial showed positive outcomes in fibrosis improvement and MASH resolution, with pegozafermin demonstrating a favorable safety profile. The company is advancing into Phase 3 trials for both cirrhotic and non-cirrhotic patients, building on the promising results of the ENLIVEN study.
89bio公司宣布了其20亿期ENLIVEN试验中pegozafermin的新分析,旨在治疗伴有高级纤维化的代谢功能障碍相关性脂肪肝炎(MASH)。这些研究结果在圣地亚哥的肝脏会议上发布,表明pegozafermin在逆转纤维化和防止进展为肝硬化方面的有效性。首席医疗官Hank Mansbach对结果表示兴奋,而Dr. Naim Alkhouri则强调非侵入性检测识别高风险患者的潜力。试验显示在改善纤维化和解决MASH方面的积极结果,同时pegozafermin展示了良好的安全性。该公司正朝着肝硬化和非肝硬化患者的3期试验迈进,以基于ENLIVEN研究的乐观结果。
Potential Positives
潜在的积极因素
- Presentation of new analyses from the Phase 2b ENLIVEN trial at a major medical conference highlights the company's ongoing research and commitment to addressing liver diseases.
- Positive data may enhance investor confidence and support the progression of pegozafermin through clinical trials, potentially leading to further development milestones.
- Pegozafermin's designation as a Breakthrough Therapy by the FDA and Priority Medicines status by the EMA underscores its significant therapeutic potential in treating MASH, attracting attention and credibility to 89bio's pipeline.
- 在一场主要医学会议上对20亿期ENLIVEN试验的新分析的展示突显了该公司在研究和解决肝病方面的持续承诺。
- 积极的数据可能增强投资者信心,并支持pegozafermin在临床试验中的进展,可能导致进一步的发展里程碑。
- pegozafermin被FDA指定为突破疗法,并获得EMA优先药物的地位,这突显了其在治疗MASH方面的重大治疗潜力,为89bio的产品线吸引了关注和信誉。
Potential Negatives
潜在负面影响
- Potential overreliance on post-hoc analyses from the Phase 2b ENLIVEN trial, which may not be as robust as primary clinical trial results.
- Risks and uncertainties are highlighted in the forward-looking statements, indicating potential challenges with future trial outcomes and regulatory approvals.
- Possible dependence on a single product candidate (pegozafermin), leading to increased vulnerability if it fails to receive expected approvals or positive results from ongoing trials.
- 可能过度依赖于20亿ENLIVEN试验的事后分析,这些分析可能没有主要临床试验结果那么可靠。
- 在前瞻性声明中强调了风险和不确定性,表明未来试验结果和监管批准可能面临挑战。
- 可能过于依赖单一产品候选药物(pegozafermin),如果未能获得预期的批准或正在进行的试验中未能获得积极结果,将导致脆弱性增加。
FAQ
FAQ
What is the ENLIVEN trial about?
ENLIVEN试验是关于什么的?
The ENLIVEN trial is a Phase 2b study evaluating the safety and efficacy of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH).
ENLIVEN试验是一个20亿阶段的研究,评估pegozafermin在代谢功能障碍相关脂肪性肝炎(MASH)患者中的安全性和有效性。
What are the key findings from the recent analyses?
最近分析的主要发现是什么?
The analyses indicated pegozafermin's effectiveness in reversing fibrosis and preventing cirrhosis in advanced MASH patients.
分析表明,pegozafermin在逆转纤维化和预防晚期MASH患者的肝硬化方面的有效性。
What is pegozafermin?
pegoxafermin是什么?
Pegozafermin is a glycoPEGylated analog of FGF21, developed for treating metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
pegoxafermin是一种糖基PEG化的FGF21类似物,旨在治疗与代谢功能障碍相关的脂肪性肝炎(MASH)和严重高甘油三酯血症(SHTG)。
How was the trial designed?
试验是如何设计的?
The trial was a multicenter, randomized, double-blind study involving 192 patients dosed with varying amounts of pegozafermin or placebo.
该试验为多中心、随机、双盲研究,涉及192名患者,他们接受了不同剂量的pegoxafermin或安慰剂。
What does "Breakthrough Therapy" designation mean?
"突破性疗法"的指定是什么意思?
The "Breakthrough Therapy" designation from the FDA indicates pegozafermin shows significant potential to treat serious conditions like MASH with fibrosis.
FDA的"突破性疗法"指定表明,pegoxafermin在治疗严重疾病(如伴纤维化的MASH)方面显示出显著潜力。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免责声明:这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。
$ETNB Insider Trading Activity
$ETNb内幕交易活动
$ETNB insiders have traded $ETNB stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
$ETNb内部人士在过去6个月内在公开市场上交易了$ETNb股票1次。在这些交易中,0次是购买,1次是出售。
Here's a breakdown of recent trading of $ETNB stock by insiders over the last 6 months:
以下是过去6个月内部人士对$ETNb股票近期交易的详细信息:
- QUOC LE-NGUYEN (See Remarks) sold 27,955 shares.
- QUOC LE-NGUYEN(详见备注)出售了27,955股。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟踪内部交易,请查看Quiver Quantitative的内部交易特斯拉-仪表。
$ETNB Hedge Fund Activity
$ETNb对冲基金活动
We have seen 84 institutional investors add shares of $ETNB stock to their portfolio, and 72 decrease their positions in their most recent quarter.
我们看到84家机构投资者在他们的投资组合中增加了$ETNb股票的股份,而72家在最近的一个季度减少了他们的持仓。
Here are some of the largest recent moves:
以下是一些最近最大的交易动态:
- BVF INC/IL added 3,521,125 shares (+87.0%) to their portfolio in Q2 2024
- HOLOCENE ADVISORS, LP removed 3,450,689 shares (-100.0%) from their portfolio in Q2 2024
- SUVRETTA CAPITAL MANAGEMENT, LLC added 1,733,841 shares (+27.5%) to their portfolio in Q2 2024
- RA CAPITAL MANAGEMENT, L.P. added 1,408,450 shares (+11.0%) to their portfolio in Q2 2024
- MPM BIOIMPACT LLC removed 791,736 shares (-70.6%) from their portfolio in Q3 2024
- ORCHARD CAPITAL MANAGEMENT, LLC removed 697,334 shares (-94.3%) from their portfolio in Q3 2024
- WESTFIELD CAPITAL MANAGEMENT CO LP added 686,673 shares (+29.6%) to their portfolio in Q3 2024
- BVF INC/IL在2024年第二季度新增了3,521,125股(+87.0%)到他们的投资组合中。
- HOLOCENE ADVISORS, LP在2024年第二季度从他们的投资组合中移除3,450,689股(-100.0%)。
- SUVRETTA CAPITAL MANAGEMENt, LLC 在2024年第二季度增持了1,733,841股(+27.5%)到他们的投资组合中
- RA CAPITAL MANAGEMENt, L.P. 在2024年第二季度增持了1,408,450股(+11.0%)到他们的投资组合中
- MPm BIOIMPACT LLC在2024年第三季度移除791,736股(-70.6%)从他们的投资组合中。
- ORCHARD CAPITAL 资产管理有限公司在2024年第三季度将其投资组合中的697,334股(-94.3%)剔除。
- WESTFIELD CAPITAL MANAGEMENt CO LP 在2024年第三季度增持了686,673股(+29.6%)到他们的投资组合中
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要追踪对冲基金的股票组合,请查看Quiver Quantitative的机构持股仪表板。
Full Release
全面发布
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in metabolic dysfunction-associated steatohepatitis (MASH) patients with advanced fibrosis. The findings were presented in four poster sessions at The American Association for the Study of Liver Diseases (AASLD) The Liver Meeting
being held in San Diego, California.
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced new analyses of data from the Phase 20亿 ENLIVEN trial evaluating pegozafermin in metabolic dysfunction-associated steatohepatitis (MASH) patients with advanced fibrosis. The findings were presented in four poster sessions at The American Association for the Study of Liver Diseases (AASLD) The Liver Meeting
being held in San Diego, California.
"We are excited to present additional analyses from our Phase 2b ENLIVEN trial at this year's Liver Meeting, which reinforce pegozafermin's potential effectiveness in reversing fibrosis and preventing progression to cirrhosis in patients with advanced MASH," said Hank Mansbach, Chief Medical Officer of 89bio. "These analyses strengthen our confidence in the design of our Phase 3 trials for both cirrhotic and non-cirrhotic MASH, and we look forward to building on this momentum as we advance these trials."
"MASH is often underdiagnosed and undertreated, which can lead to cirrhosis and severe complications like the need for liver transplantation," said Naim Alkhouri, MD, Chief Medical Officer, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH). "These post-hoc analyses demonstrate the potential of NITs like FAST and AGILE3+ to identify high-risk patients more conveniently, potentially reducing the need for liver biopsy. The results show that pegozafermin not only improved patients' FAST scores but also achieved both MASH resolution and fibrosis improvement, indicating its potential as a treatment option for patients with advanced MASH."
“我们很高兴在今年的肝脏会议上展示来自我们20亿阶段ENLIVEN试验的额外分析,这进一步验证了pegozafermin在逆转纤维化和防止在进展性MASH患者中进展到肝硬化方面的潜在效用,”89bio的首席医学官Hank Mansbach说道。“这些分析增强了我们对肝硬化和非肝硬化MASH的三期临床试验设计的信心,我们期待着在推进这些试验的过程中继续积累这样的动力。”
“MASH常常被低估并且治疗不足,这可能导致肝硬化以及需要肝脏移植等严重并发症,”亚利桑那州肝脏健康公司(ALH)首席医学官、移植肝病学主任及脂肪肝项目主任Naim Alkhouri医生说。“这些后期分析显示了像FASt和AGILE3+这样的NITs有潜力更便捷地识别高风险患者,有可能减少肝活检的需求。结果显示,pegozafermin不仅改进了患者的FASt评分,还实现了MASH的缓解和纤维化的改善,指示其作为进展性MASH患者治疗选择的潜力。”
Publications Presented at the Meeting:
Publications Presented at the Meeting:
-
Pegozafermin reduced progression to cirrhosis: A post-hoc analysis from the Phase 2b ENLIVEN study (Publication 1563).
-
Biomarker response in metabolic dysfunction-associated steatohepatitis (MASH) patients with high-risk baseline FAST scores: Observations from the ENLIVEN Phase 2b trial with pegozafermin (Publication 1549).
-
Diagnostic potential of FAST and AGILE3+ scores for F2/F3 fibrosis: An analysis of the Phase 2 ENLIVEN study (Publication 2014).
-
Analysis and integration of machine learning for biomarker assessments and their association with treatment response: Insights from the ENLIVEN Phase 2b trial of pegozafermin (Publication 2008)
-
Pegozafermin减少了肝硬化的进展:来自20亿阶段ENLIVEN研究的后期分析(出版物1563)。
-
高风险基础FASt评分的代谢功能障碍相关性脂肪性肝炎(MASH)患者的生物标志物反应:来自ENLIVEN Phase 20亿试验与pegozafermin的观察(出版物1549)。
-
FASt和AGILE3+评分对F2/F3纤维化的诊断潜力:Phase 2 ENLIVEN研究的分析(出版物2014)。
-
对生物标志物评估的机器学习分析和整合及其与治疗反应的关联:来自ENLIVEN第20亿次试验关于pegozafermin的见解(出版物2008)
A copy of the AASLD posters will be accessible under "Scientific Publications" in the pipeline section of
89bio's website
.
AASLD海报的副本将可以在"科学出版物"下方的pipeline部分访问
89bio的网站
.
About ENLIVEN
ENLIVEN was a multicenter, randomized, double-blind, placebo-controlled Phase 2b trial designed to evaluate the safety and efficacy of weekly or every-two-week dosing of pegozafermin for the treatment of patients with biopsy confirmed MASH and NAS ≥ 4 for 48 weeks. In the trial, 192 patients were dosed with pegozafermin 15mg QW, 30mg QW and 44mg Q2W, or placebo. Primary outcomes measured were proportion of participants with resolution of MASH without worsening of fibrosis and proportion of participants with ≥1 stage decrease in fibrosis stage with no worsening of MASH at week 24. Secondary measures included change from baseline in liver fat, liver enzymes, noninvasive markers of liver fibrosis, glycemic control, lipoproteins, and body weight as well as safety and tolerability measures. Patients who entered the blinded extension phase were subsequently treated for an additional 24 weeks for a total treatment period of 48 weeks. Some patients who were on placebo (n=19) were re-randomized to receive pegozafermin in the extension phase. Key endpoints in the extension phase include liver fat and noninvasive markers of liver fibrosis and inflammation. ENLIVEN achieved high statistical significance on primary histology endpoints with 30mg QW and 44mg Q2W dosing at week 24 and the results were published in the New England Journal of Medicine. To learn more about the clinical trial, visit clinicaltrials.gov: NCT04929483.
关于ENLIVEN
ENLIVEN是一个多中心、随机、双盲、安慰剂对照的Phase 20亿试验,旨在评估每周或每两周一次给药pegozafermin在治疗病理确认的MASH及NAS ≥ 4的患者中的安全性和有效性,为期48周。在试验中,192名患者接受了pegozafermin 15mg QW,30mg QW和44mg Q2W,或安慰剂的治疗。主要评估指标是MASH缓解而纤维化未恶化的参与者比例,以及在第24周,Fibrosis阶段≥1级降低且MASH未恶化的参与者比例。次要指标包括肝脏脂肪、肝脏酶、非侵入性肝纤维化标志物、血糖控制、脂蛋白和体重的基线变化,以及安全性和耐受性指标。进入盲法延续阶段的患者随后接受了额外的24周治疗,总治疗周期为48周。一些使用安慰剂的患者(n=19)在延续阶段被重新随机接受pegozafermin治疗。延续阶段的关键终点包括肝脏脂肪和非侵入性肝纤维化及炎症标志物。ENLIVEN在第24周以30mg QW和44mg Q2W给药实现了主要组织学终点的高统计学显著性,结果发表在新英格兰医学杂志。想了解更多关于临床试验的信息,请访问clinicaltrials.gov:NCT04929483。
About pegozafermin
Pegozafermin is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). FGF21 is an endogenous hormone that has broad effects such as regulating energy expenditure, glucose and lipid metabolism. In clinical trials, pegozafermin has demonstrated direct anti-fibrotic and anti-inflammatory effects on the liver, as well as reduced triglyceride levels, improved insulin resistance and glycemic control, and continued to demonstrate a favorable safety and tolerability profile. Pegozafermin received Breakthrough Therapy designation (BTD) status from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) status from the European Medicines Agency (EMA) for the treatment of MASH with fibrosis. Pegozafermin is being studied in the Phase 3 ENLIGHTEN trial program for MASH and the Phase 3 ENTRUST trial for SHTG.
关于佩戈扎费明
佩戈扎非明是一种专门设计的糖基PEG化成纤维细胞生长因子21(FGF21)类药物,正在开发用于治疗代谢功能障碍相关性脂肪肝炎(MASH)和严重高甘油三酯血症(SHTG)。FGF21是一种内源性激素,具有广泛的影响,如调节能量消耗、葡萄糖和脂质代谢。在临床试验中,佩戈扎非明表现出对肝脏的直接抗纤维化和抗炎作用,降低甘油三酯水平,提高胰岛素抵抗和血糖控制,并持续展现出良好的安全性和耐受性特征。佩戈扎非明获得了美国食品和药物管理局(FDA)的突破性疗法认定(BTD)和欧洲药品管理局(EMA)的优先药品(PRIME)地位,以治疗具有纤维化的MASH。佩戈扎非明正在第3期ENLIGHTEN试验项目中研究MASH,并在第3期ENTRUSt试验中研究SHTG。
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit
or follow the company on
LinkedIn
.
关于89Bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit
or follow the company on
LinkedIn
.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, statements regarding the therapeutic potential and utility, efficacy and clinical benefits of pegozafermin, the safety and tolerability profile of pegozafermin and trial designs, clinical development plans and timing for pegozafermin, including confirming the long-term efficacy, tolerability and sustained improvement in key liver health markers observed in the Phase 2b ENLIVEN trial evaluating pegozafermin in the current Phase 3 trials for both cirrhotic and non-cirrhotic MASH. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "anticipate," "goal," "opportunity," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While 89bio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in 89bio's filings with the Securities and Exchange Commission (SEC)), many of which are beyond 89bio's control and subject to change. Actual results could be materially different. Risks and uncertainties include: expectations regarding the design of the ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis trials; expectations regarding the timing and outcome of the ENTRUST Phase 3 trial in SHTG; 89bio's ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; receipt of BTD for pegozafermin in MASH may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA; 89bio's substantial dependence on the success of its lead product candidate; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of 89bio's capital resources and its ability to raise additional capital; and other risks and uncertainties identified in 89bio's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and other subsequent disclosure documents filed with the SEC. 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
前瞻性声明
本新闻稿中的某些声明可能构成根据联邦证券法的“前瞻性声明”,包括但不限于关于pegozafermin的治疗潜力和用途、疗效和临床益处、pegozafermin的安全性和耐受性特征以及试验设计、临床开发计划和pegozafermin的时间安排的声明,包括确认在当前针对肝硬化和非肝硬化MASH的第三阶段试验中评估pegozafermin的20亿ENLIVEN试验中观察到的长期疗效、耐受性和关键肝脏健康指标的持续改善。诸如“可能”、“或许”、“将”、“目标”、“打算”、“应该”、“能够”、“会”、“期待”、“相信”、“设计”、“估计”、“预测”、“潜力”、“预期”、“目标”、“机会”、“开发”、“计划”或这些术语的否定形式,以及类似的表达或关于意图、信念或当前期望的声明,均为前瞻性声明。虽然89bio认为这些前瞻性声明是合理的,但不应对任何此类前瞻性声明过度依赖,这些声明基于我们在本发布之日可获得的信息。这些前瞻性声明基于当前的估计和假设,并受到各种风险和不确定性的影响(包括但不限于在89bio向证券交易委员会(SEC)提交的文件中列出的风险),这些风险中的许多超出89bio的控制范围并可能发生变化。实际结果可能会有重大不同。风险和不确定性包括:关于ENLIGHTEN-Fibrosis和ENLIGHTEN-Cirrhosis试验设计的期望;关于SHTG中ENTRUSt第三阶段试验的时间和结果的期望;89bio执行其策略的能力;来自临床研究的积极结果可能不一定对未来或正在进行的临床研究的结果具有预测性;在MASH中获得pegozafermin的BTD可能不会导致比在传统FDA程序中考虑审批的药物更快的开发过程、审查或批准,并不保证最终获得FDA的批准;89bio在其首要产品候选药物成功上的重大依赖;来自竞争产品的竞争;美国或国际上一般经济、健康、工业或政治条件的影响;89bio资本资源的充分性及其筹集额外资本的能力;以及在89bio截至2024年9月30日的季度10-Q表中的其他风险和不确定性,以及与SEC提交的其他后续披露文件中的其他风险和不确定性。89bio主张根据1995年《私人证券诉讼改革法》对前瞻性声明享有安全港保护。89bio明确拒绝任何因新信息、未来事件或其他原因对任何声明进行更新或更改的义务,除非法律要求。
Investor Contacts:
Annie Chang
89bio, Inc.
investors@89bio.com
投资者联系方式:
Annie Chang
89bio公司
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
媒体联系:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com